ReviewDrugs in context2020
Management of type 2 diabetes: consensus of diabetes organizations.
Review in Drugs in context, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Comparative effectiveness of semaglutideFrontiers in pharmacology · 2025Pooled it
- Circulating osteogenic progenitors and osteoclast precursors are associated with long-term glycemic control, sex steroids, and visceral adipose tissue in men with type 2 diabetes mellitus.Frontiers in endocrinology · 2022Trial
- Evaluation of continuous glucose monitoring outcomes and health care resource utilization in patients with non-insulin-treated type 2 diabetes.Journal of managed care & specialty pharmacy · 2026Article
- A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists.Journal of clinical medicine · 2026Review
- Type 2 Diabetes Mellitus in Saudi Arabia: Prevalence, Risk Factors, and Management Strategies: A Review.Endocrine, metabolic & immune disorders drug targets · 2026Review
- Machine learning driven diabetes care using predictive-prescriptive analytics for personalized medication prescription.Scientific reports · 2025Article
- Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action.Diabetes spectrum : a publication of the American Diabetes Association · 2024Article
- Integrated investigation and discovery of therapeutic targets for 3-hydroxybakuchiol against diabetes based on molecular docking studies and cell experiments.BMC complementary medicine and therapies · 2023Article
- Review
- The impact of the COVID-19 pandemic in diabetes and dyslipidemia management in a Spanish region: a retrospective study of the Aragon population.Frontiers in medicine · 2023Article
- One-Year Mean A1c of > 7% is Associated with Poor Bone Microarchitecture and Strength in Men with Type 2 Diabetes Mellitus.Calcified tissue international · 2022Article
- Icariside II Exerts Anti-Type 2 Diabetic Effect by Targeting PPARα/γ: Involvement of ROS/NF-κB/IRS1 Signaling Pathway.Antioxidants (Basel, Switzerland) · 2022Article
- α-Glucosidase inhibitory activity of cannabidiol, tetrahydrocannabinol and standardized cannabinoid extracts fromCurrent research in food science · 2022Article
- Diabetes Mellitus and Its Implications in Aortic Stenosis Patients.International journal of molecular sciences · 2021Review
- Tractography in Type 2 Diabetes Mellitus With Subjective Memory Complaints: A Diffusion Tensor Imaging Study.Frontiers in neuroscience · 2021Article
- Network Pharmacology-Based Identification of the Mechanisms of Shen-Qi Compound Formula in Treating Diabetes Mellitus.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Antidiabetic and antioxidant potential of Crocin in high-fat diet plus streptozotocin-induced type-2 diabetic rats.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the advances in diabetes management, people with diabetes are not reaching their target glycemic goals. Healthcare professionals often fail to initiate, escalate, or de-intensify therapy when indicated. There are several organizations that provide guidance on the management of diabetes to assist the practitioner in achieving improved glycemic control, and this can cause confusion to the practitioner on which organizations' guidance to follow. Diabetes mellitus is associated with an elevated risk of cardiovascular disease, and there have been studies that suggest some antidiabetic medications increase cardiovascular risk and some reduce cardiovascular risk. Diabetes organizations recommend the individualization of treatment goals and choices of drug therapy that will be safe and effective. Healthcare professionals should be knowledgeable and equipped to decide on the best treatment regimen for each of their patients with type 2 diabetes (T2D) and be familiar with how to utilize the different organizations' philosophies in treating their patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.